It is well established that use of GLP-1RA reduced all component of MACE, all causes mortality, hospitalization for heart failure, delayed kidney function deterioration although its benefits varied depending on different structure of GLP-RA. Additional benefits on erectile dysfunction and cognitive dysfunction were also reported. In real world data obtained from Japan, use of GLP-1 RA were associated with improvement of HbA1c, body weight and lipid profiles with persistent rate reached 65%-70% at 18 months after initial use in dulagutide group. In a comparison of inclusion and exclusion criteria, it is reported that REWIND with dulaglutide once weekly might be more generalized to “3 high” (blood glucose, blood pressure, blood lipids) diabetes population in China. Further comparisons of subgroups of Asian origins in clinical trials received GLP-RA will be reviewed.